Warum Bitcoin als Wertspeicher in keinem diversifizierten Portfolio fehlen sollte. Jetzt lesen -w-
01.12.2016 12:01:00

OncoSec to Present at the 9th Annual LD Micro Main Event

SAN DIEGO, Dec. 1, 2016 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that Richard Slansky, OncoSec's Chief Financial Officer, will be presenting at the 9th annual LD Micro Main Event on December 7th at 4:00 PM PST at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. The LD Micro Main Event is the largest independent conference for small/microcap companies and will feature 240 presenting names. For more information, please visit www.ldmicro.com/events.

About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer.  ImmunoPulse® is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse® IL-12, is currently in clinical development for several indications, including metastatic melanoma, head and neck cancer, and triple-negative breast cancer. The program's current focus is on the significant unmet medical need in patients with melanoma who are refractory or non-responsive to anti-PD-1/PD-L1 therapies. In addition to ImmunoPulse® IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse® platform. For more information, please visit www.oncosec.com.

CONTACT:
Sophia Ononye, PhD MPH MBA
Associate Director, Investor Relations and Corporate Communications
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com

 

Logo - http://photos.prnewswire.com/prnh/20120905/LA68078LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oncosec-to-present-at-the-9th-annual-ld-micro-main-event-300371114.html

SOURCE OncoSec Medical Incorporated

Nachrichten zu OncoSec Medical Incmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu OncoSec Medical Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!